PharmaCyte Biotech, Inc. — Form 10-Q Summary
Reporting period: Three months ended July 31, 2015, compared with the three months ended July 31, 2014. PharmaCyte is a clinical-stage biotechnology company developing cancer and diabetes treatments using its Cell-in-a-Box technology. It reported no product revenue in either period.
Financial performance and liquidity
| Metric | Three months ended July 31, 2015 | Prior-year period or balance-sheet comparison |
|---|---|---|
| Revenue | $0 | $0 in 2014 |
| Operating expenses | $1,007,740 | $1,583,160 in 2014 |
| Operating loss | $1,007,740 | $1,583,160 in 2014 |
| Net loss | $546,164 | $1,584,824 in 2014 |
| Net cash used in operations | $1,063,517 | $786,814 in 2014 |
| Cash at period end | $2,910,201 | $2,699,737 at April 30, 2015 |
| Working capital | Approximately $1.8 million | Approximately $0.8 million at April 30, 2015 |
| Total liabilities | $1,186,186 | $2,012,415 at April 30, 2015 |
Gross margin and operating margin are not meaningful because the company had no revenue. The net loss improved substantially year over year, mainly because of a $462,303 unrealized gain from revaluing derivative warrants; this noncash gain reduced the reported loss. Lower general and administrative and legal expenses also reduced operating expenses, partly offset by higher compensation expense.
Cash increased by $210,464 during the quarter. Financing provided $1,273,822, mainly from common-stock sales; operating activities used $1,063,517, and there was no investing cash flow. The company reported no conventional debt balance on its balance sheet; current liabilities included a $700,000 cannabis-license payment obligation. Cash balances included approximately $2.66 million uninsured at one financial institution.
Business developments, outlook, and risks
- Management’s priorities include preparing an Australian Phase 2b trial for advanced, inoperable pancreatic cancer; preparing U.S. studies addressing pancreatic-cancer symptoms; and continuing preclinical work on an insulin-dependent diabetes treatment.
- Management stated that period-end cash should fund current operations and working capital for the foreseeable future, while also saying it intends to continue selling common stock to fund clinical trials. The filing provides no specific cash-runway estimate or clinical-trial timing guidance.
- The company raised approximately $1.3 million net by issuing about 9.9 million shares during the quarter. Common shares outstanding increased to 742,610,829 at July 31, from 732,760,536 at April 30. After quarter-end, it issued 817,800 additional shares for approximately $80,000. These sales and outstanding options and warrants create potential dilution.
- The cannabis license requires a $2.0 million upfront payment by December 31, 2015; $1.3 million had been paid by July 31, leaving $700,000 recorded as a current obligation. A further $100,000 was paid on August 6. The agreement also includes an $800,000 manufacturing setup fee, production costs, royalties, and milestone payments. Other development licenses also carry milestone and royalty commitments contingent on progress and commercialization.
- Related-party arrangements include purchases of approximately $48,000 from Austrianova subsidiaries and approximately $8,000 in consulting payments to a company owned by SG Austria officers during the quarter.
- Management concluded that disclosure controls were ineffective because of material weaknesses involving corporate governance, internal communication, control documentation, segregation of duties, and IT controls. Remediation was planned for fiscal 2016, but no such changes had yet been made. Management warned that remaining weaknesses could lead to material misstatement or a restatement.
- The company reported no material pending legal proceedings and no material changes in risk factors from its 2015 Form 10-K. It has a history of operating losses, no recognized income-tax benefit, and a valuation allowance against deferred tax assets.
Important facts for investors to verify
- Progress, regulatory readiness, funding, and expected timing of the planned cancer trials and diabetes preclinical studies.
- Whether the company can meet the remaining cannabis-license payment and other development commitments without substantial additional equity financing.
- Cash burn and liquidity needs relative to management’s “foreseeable future” assertion, particularly given the absence of revenue.
- Changes in share count and the potential dilution from future stock sales, options, and warrants.
- Whether material weaknesses in internal control are remediated and whether the derivative-liability valuation changes materially.